These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16410363)

  • 21. Combination of trastuzumab and vinorelbine in metastatic breast cancer.
    Suzuki Y; Tokuda Y; Saito Y; Ohta M; Tajima T
    Jpn J Clin Oncol; 2003 Oct; 33(10):514-7. PubMed ID: 14623919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
    Harris LN; You F; Schnitt SJ; Witkiewicz A; Lu X; Sgroi D; Ryan PD; Come SE; Burstein HJ; Lesnikoski BA; Kamma M; Friedman PN; Gelman R; Iglehart JD; Winer EP
    Clin Cancer Res; 2007 Feb; 13(4):1198-207. PubMed ID: 17317830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.
    Chan A
    Ann Oncol; 2007 Jul; 18(7):1152-8. PubMed ID: 17264064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
    Goh G; Schmid R; Guiver K; Arpornwirat W; Chitapanarux I; Ganju V; Im SA; Kim SB; Dechaphunkul A; Maneechavakajorn J; Spector N; Yau T; Afrit M; Ahmed SB; Johnston SR; Gibson N; Uttenreuther-Fischer M; Herrero J; Swanton C
    PLoS Med; 2016 Dec; 13(12):e1002136. PubMed ID: 27923043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A pilot study of trastuzumab and vinorelbine-combined therapy for metastatic breast cancer].
    Onishi I; Tsugawa K; Nakamura M; Nishimura G; Fujimura T; Taniya T; Kayahara M; Shimizu K; Ohta T; Miwa K
    Gan To Kagaku Ryoho; 2004 May; 31(5):743-6. PubMed ID: 15170984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Bayo-Calero JL; Mayordomo JI; Sánchez-Rovira P; Pérez-Carrión R; Illaramendi JJ; García-Bueno JM; González-Flores E; Crespo C; Ramos-Vázquez M; García-Palomo A; Ruiz-Borrego M; de la Haba J; Gómez-Bernal A; Yubero-Esteban A
    Clin Breast Cancer; 2008 Jun; 8(3):264-8. PubMed ID: 18650157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.
    Lin NU; Seah DS; Gelman R; Desantis S; Mayer EL; Isakoff S; Dipiro P; Krop IE; Come SE; Weckstein D; Winer EP; Burstein HJ
    Breast Cancer Res Treat; 2013 Jun; 139(2):403-10. PubMed ID: 23645007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer.
    Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Bachleitner-Hoffmann T; Locker GJ; Rudas M; Mader R; Zielinski CC; Steger GG
    Breast Cancer Res Treat; 2007 May; 102(3):375-81. PubMed ID: 17028979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
    Han HS; Kim JS; Park JH; Jeon YK; Lee KW; Oh DY; Kim JH; Park SY; Im SA; Kim TY; Park IA; Bang YJ
    J Korean Med Sci; 2009 Oct; 24(5):910-7. PubMed ID: 19794992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study].
    Bian L; Xu BH; Di LJ; Wang T; Wang XJ; Jiao SC; Yang JL; Tong ZS; Liu J; Feng JF; Liu DG; Yu QT; Liu YP; Ma Y; Yu H; Jiang ZF
    Zhonghua Yi Xue Za Zhi; 2020 Aug; 100(30):2351-2357. PubMed ID: 32791810
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.
    Tryfonidis K; Marreaud S; Khaled H; De Valk B; Vermorken J; Welnicka-Jaskiewicz M; Aalders K; Bartlett JMS; Biganzoli L; Bogaerts J; Cameron D;
    Breast Cancer Res Treat; 2017 Jun; 163(3):507-515. PubMed ID: 28324265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
    Seidman AD; Fornier MN; Esteva FJ; Tan L; Kaptain S; Bach A; Panageas KS; Arroyo C; Valero V; Currie V; Gilewski T; Theodoulou M; Moynahan ME; Moasser M; Sklarin N; Dickler M; D'Andrea G; Cristofanilli M; Rivera E; Hortobagyi GN; Norton L; Hudis CA
    J Clin Oncol; 2001 May; 19(10):2587-95. PubMed ID: 11352950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination.
    Catania C; Medici M; Magni E; Munzone E; Cardinale D; Adamoli L; Sanna G; Minchella I; Radice D; Goldhirsch A; Nolè F
    Ann Oncol; 2007 Dec; 18(12):1969-75. PubMed ID: 17846020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.
    Chan A; Shannon C; de Boer R; Baron-Hay S; Redfern A; Bauwens A; Craft P; Webb S; Townsend A; Kotasek D
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):368-75. PubMed ID: 25351929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab/chemotherapy combinations in metastatic breast cancer.
    Ligibel JA; Winer EP
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.